A New Therapeutic

Cancer, autoimmunity and other diseases
are enabled by bad signal molecules.

Ntercept is a powerful new “nano-scavenger”
for treating disease by removing these circulating targets
specifically without drugs, radiation or other harsh methods.

About Ntercept

Cells talk to each other - a LOT. Just about every cell type in our bodies is constantly sending and receiving messages via tiny (virus-sized) molecules called cell signals. These signals actually induce receiving cells to change their behavior - to increase or decrease production of certain chemicals – or even commit suicide. Like good kids in a bad neighborhood, normal cells can do bad things when directed to do so by bad cell signals. New research increasingly demonstrates that non-infectious diseases as disparate as cancer, autoimmune disease, diabetes and alzheimer’s are fundamentally driven by aberrant cell signals.

Over the last decade, this understanding has given rise to the new field of Systems Biology (aka Network Medicine), which emphasizes that living things are first and foremost informational systems, in which health equates with a balanced flow of information and pathologies equate with an imbalanced flow. This is a transformative insight, but a limited one as well, given that there’s been no platform for treating disease via modulation of specific cell signals.

Until now. Ntercept is a powerful new class of therapy, a special nano-particle (NP) called a nano-scavenger, for treating disease via in vivo adsorption and clearance of specific circulating signal molecules and/or their inhibitors. Although infused like a drug, nano-scavengers actually meet the definition of a device in some markets, potentially shortening the approval process significantly. Ntercept is being built from FDA-approved biocompatible materials, and incorporates a patent-pending shield against all cell surface interactions - the root cause of most drug side effects.

The first instance of Ntercept will be Ntercept/Onco, for treating solid tumor cancers (all types) by scavenging immune inhibitors generated by all cancerous tumors as a way of evading immune attack. Conventional cancer immunotherapies block the ability of immune cells to down-regulate when directed to do so by tumors. While this can induce tumor regression, it can also induce serious immune-related adverse events, including death. Ntercept/Onco is being designed to scavenge immune inhibitors directly without affecting immune cells themselves, thus avoiding such problems.

How it Works

The specific geometry and materials used in the Ntercept NP are confidential, for discussion under NDA with qualified investors. The central challenge our team had to overcome – reflected in our pending patents – is this: Various molecules are available for incorporation into an NP to bind to and thereby capture circulating targets. However, molecules that bind to bioactive targets tend themselves to be bioactive at the surface of various cells; infusing such binding molecules in a “raw” or unshielded state tends to have unpredictable and potentially undesirable effects due to cell surface interactions. Ntercept uses a novel combination of geometry and biochemistry to enable capture of circulating targets while simultaneously shielding the binding molecules within the NP against ALL cell surface interactions. The Ntercept NP will literally bounce off cells without affecting them in any way.

Ntercept is a true platform because all that's required to change the cell signal being targeted by the nano-scavenger – and thus the disease being treated – is to swap the binding molecule at the core of the NP. The NP itself does not have to be modified at all. This will result in increasingly rapid development of new therapeutics, and increasing rapid regulatory approval as well, as the relevant agencies become familiar with the Ntercept architecture and safety profile.

While Ntercept/Onco is just now being engineered in the real world, it was recently the subject of a detailed in silico study employing the world’s most advanced mathematical and algorithm model of the tumor microenvironment to project the in vivo behavior of this new nano-scavenger. The results exceeded all expectations; the resulting report is available for review by qualified investors under NDA.


CEO: Lou Hawthorne

  • Ntercept inventor
  • BA, Princeton, 1983
  • Numerous patents/pending
  • Commercialized cloning
  • Embryology: 1997-2008
  • Cancer R&D since 2008
  • 3 years in private equity
  • Many years in AI & other tech
  • Skilled team builder/manager

CMO: DeLeys Brandman

  • MD, UCLA
  • MPH, UC Berkeley
  • 30 years in health & biotech
  • Extensive global experience
  • High level insurance industry
  • Former SVP, Aetna
  • Founder of non-profit:
Compassionate Access, for small clinical trials

CTO: John Dodgson, PhD

  • PhD, Newcastle University
  • Expert in micro & nano 
  • IP creation (30+ patents)
  • Patent engineering, analysis & drafting
  • Specialities: Regen med, stem cells, medtech, IVF, embryology, cloning, electrophysiology, cold chain, cancer immunotherapy
  • Based in London

CSO: Currently Recruiting

  • MD / PhD
  • Strong in biochemistry
  • Strong in immunology
  • Drug design experience
  • Nano experience
  • Clinical trial experience

Scientific Advisory Board

Gamal Akabani, PhD

Director, Nuclear Imaging
Texas Institute for
Preclinical Studies
Former FDA Senior Staff Fellow

Keith Block, MD

Medical-Scientific Director
Block Center for Integrative
Cancer Treatment

Robert E. Burrell, PhD

Canada Research Chair in Nanostructured Biomaterials
Chair, Biomedical Engineering
University of Alberta

Ron Chiarello, PhD

CEO, Alveo Technologies
Developing detectors to pair
with Ntercept therapeutics

Richard Cutler, PhD

Past Director,
Anti-Aging Research, NIH

Aubrey de Grey, PhD

CSO, SENS Research Foundation

Mitchell Harmon, MD, PhD

Chief, Endocrinology Section
Dept. of Medicine at VA

Stuart Helfand, DVM

Veterinary Oncology Oregon Health & Science University

Babak Kateb, Director

National Center for

Editor, Nano-neurosurgery

Brian Kennedy, PhD

CEO, Buck Institute for
Research on Aging

Dobri Kiprov, M.D.

Chief, Division of Immunotherapy
California Pacific Medical Center
International Expert in Apheresis

Sumita Pennathur, PhD

Associate Professor, UCSB
Author: 3 books on nanotech
CSO: Alveo

Kevin Perrott, ~PhD

Scientist, Buck Institute
Co-founder, SENS Foundation

Heiko Rieger, PhD

Professor of Theoretical Physics
Saarland University, Germany
Expert: Tumor Modeling

J. Marty Tenenbaum, PhD

Founder & Chairman
Cancer Commons


Ntercept, LLC has been formed and holds several broad pending patents on the technology. Seed funding has been provided by a small group of strategic investors (including the founder of one of the world's largest life science supply companies); the company is now finalizing a Series A. We are partnering with one of the top nano-medicine groups in the world to develop the NP and test in mice, and are also partnering with a comparably advanced veterinary college for our canine studies, which will serve both as the second species for human regulatory approval as well as the basis of a valuable veterinary product.

Contact Us

Please select your area of interest:

Your Name (required)

Your Email (required)


Your Message